Advertisement

Autologous Stem Cell Transplantation

  • Alessandro ReEmail author
  • Amrita Krishnan
  • Marcus Hentrich
Chapter

Abstract

Autologous stem cell transplantation (ASCT) is a treatment strategy that allows for the administration of higher than usual doses of myelotoxic chemotherapy and/or radiation therapy to treat several hematologic and nonhematologic malignancies. High-dose chemotherapy (HDT) with ASCT is widely performed in HIV-negative patients with Hodgkin (HL) and non-Hodgkin lymphoma (NHL) and is standard therapy for refractory and relapsed patients, based on results of phase III trials. It is also used as part of initial therapy for aggressive NHL, particularly in patients with poor prognostic factors at diagnosis. In earlier eras, this treatment approach has been considered prohibitive in HIV-positive patients, because of the potential toxicity and risk of worsening immune function, thereby accelerating the course of HIV infection. The introduction of combination antiretroviral therapy (cART) in the mid-1990s has led to improvement of immune function and reduced morbidity of HIV-infected patients, thus allowing more aggressive treatment strategies including HDT and ASCT in cART-treated patients. Moreover, the use of peripheral blood stem cells instead of bone marrow significantly shortens the time to engraftment after HDT and has helped to further reduce transplant-related morbidity and mortality.

Keywords

Autologous Stem Cell Transplantation International Prognostic Index Zinc Finger Nuclease Nonhematologic Malignancy Myelotoxic Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Philip T, Giglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin’s disease. Lancet. 1993;341:1051–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Gabarre J, Azar N, Autran B, et al. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet. 2000;355:1071–2.CrossRefPubMedGoogle Scholar
  5. 5.
    Krishnan A, Molina A, Zaia J, et al. Autologous stem cell transplantation for HIV associated lymphoma. Blood. 2001;98:3857–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Moses A, Nelson J, Bagby GC. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood. 1998;91:1479–95.PubMedGoogle Scholar
  8. 8.
    Huang SS, Barobour JD, Deeks SG, et al. Reversal of human immunodeficiency virus type 1 associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis. 2000;30:504–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Re A, Cattaneo C, Skert C, et al. Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica. 2013;98:1762–8.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003;21:4423–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Serrano D, Carrion R, Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol. 2005;3:487–94.CrossRefGoogle Scholar
  12. 12.
    Balsalobre P, Diez-Martin JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol. 2009;27:2192–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high risk HIV-associated lymphomas. Blood. 2005;105:874–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Resino S, Perez A, Seoane E, et al. Short communication: immune reconstitution after autologous peripheral blood stem cell transplantation in HIV-infected patients: might be better than expected? AIDS Res Hum Retroviruses. 2007;23:543–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Simonelli C, Zanussi S, Pratesi C, et al. Immune recovery after autologous stem cell transplantation is not different for HIV-infected versus HIV-uninfected patients with relapsed or refractory lymphoma. Clin Infect Dis. 2010;50:1672–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Tirelli U, Errante D, Spina M, et al. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin’s lymphoma. Evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Cancer. 1996;77:2127–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Levine AM, Tulpule A, Tessman D, et al. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. J Clin Oncol. 1997;15:1094–103.PubMedGoogle Scholar
  18. 18.
    Spina M, Vaccher E, Juzbasic S, et al. Human immunodeficiency virus-related non-Hodgkin lymphoma. Activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer. 2001;92:200–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Bi J, Espina BM, Tulpule A, et al. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin’s lymphoma. J Acquir Immune Defic Syndr. 2001;28:416–21.CrossRefPubMedGoogle Scholar
  20. 20.
    Gabarre J, Marcelin AG, Azar N, et al. High dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica. 2004;89:1100–8.PubMedGoogle Scholar
  21. 21.
    Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114:1306–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS malignancy consortium study 020. Biol Blood Marrow Transplant. 2008;14:59–66.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Alvarnas J, Rademacher K, Wang Y, et al. Autologous hematopoietic stem cell transplantation for chemotherapy sensitive relapsed/refractory HIV associated lymphoma. Results from the blood and marrow clinical trials network. BMT CTN0803/AIDS malignancy consortium AMC 071 trial. Blood 2014;abstr. 674.Google Scholar
  24. 24.
    Serrano D, Miralles P, Carrion R, et al. Long-term follow-up of autologous stem cell transplant in AIDS-related lymphoma patients. Results of Spanish Cooperative Registry GELTAMO/GESIDA. Bone Marrow Transplant. 2010;45:abstr. 822.Google Scholar
  25. 25.
    Re A, Casari S, Cattaneo C, et al. Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer. 2001;92:2739–45.CrossRefPubMedGoogle Scholar
  26. 26.
    Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014;20:1877–84.CrossRefPubMedGoogle Scholar
  27. 27.
    The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.CrossRefGoogle Scholar
  28. 28.
    Rossi G, Donisi A, Casari S, et al. The international prognostic index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer. 1999;86:2391–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Re A, Cattaneo C, Casari S, et al. Early consolidation with high dose therapy and autologous stem cell transplantation in HIV-associated non Hodgkin lymphoma at high risk (aa-IPI 2-3). Mature results of a multicenter prospective Phase II trial. Blood. 2014;abstr. 2528.Google Scholar
  30. 30.
    Diez-Martin JL, Balsalobre P, Re A, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. European group for blood and marrow transplant. Blood. 2009;113:6011–4.CrossRefPubMedGoogle Scholar
  31. 31.
    Krishnan A, Palmer JM, Zaia JA, Tsai NC, Alvarnas J. HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant. 2010;16:1302–8.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–77.CrossRefPubMedGoogle Scholar
  33. 33.
    Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell transplantation. Blood. 2011;117:2791–9.CrossRefPubMedGoogle Scholar
  34. 34.
    DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med. 2010;2:1–8.CrossRefGoogle Scholar
  35. 35.
    Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood. 2012;120:3635–46.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370:901–10.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Morawa E, Martin P, Gergis U, et al. Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. Leuk Lymphoma. 2013;54:885–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Alessandro Re
    • 1
    Email author
  • Amrita Krishnan
    • 2
  • Marcus Hentrich
    • 3
  1. 1.Department of HematologySpedali CiviliBresciaItaly
  2. 2.Department of Hematology and Hematopoietic Cell TransplantationCity of Hope Medical CenterDuarteUSA
  3. 3.Department of Hematology and OncologyRed Cross Hospital, University of MunichMunichGermany

Personalised recommendations